Sentiment-Signal
27,1
Bearisch
Composite Score (0–100)
Insider (25%)
29.9
1 Insider, 2,0M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (23.02.2026)
HOCH Abgang Schlüsselpersonen (23.02.2026)
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 23.02.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nge Act. ☐. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Of |
| 07.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ☐. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Cert |
| 23.09.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 06.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 01.09.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Ap |
| 22.05.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | nt to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Director |
Stammdaten
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
Unternehmen & Branche
| Name | Oncology Institute, Inc. |
|---|---|
| Ticker | TOI |
| CIK | 0001799191 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Care Facilities |
| SIC | 8011 · Services-Offices & Clinics of Doctors of Medicine |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 362,2 Mio. USD |
| Beta | 0,20 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 502,729,000 | -60,606,000 | -0.54 | 164,656,000 | -15,720,000 |
| 2025-09-30 | 10-Q | 136,564,000 | -16,504,000 | -0.14 | 163,619,000 | -12,274,000 |
| 2025-06-30 | 10-Q | 119,802,000 | -17,009,000 | -0.15 | 159,798,000 | -8,985,000 |
| 2025-03-31 | 10-Q | 104,406,000 | -19,585,000 | -0.21 | 164,002,000 | 5,069,000 |
| 2024-12-31 | 10-K | 393,412,000 | -64,663,000 | -0.71 | 172,717,000 | 3,589,000 |
| 2024-09-30 | 10-Q | 99,901,000 | -16,113,000 | -0.18 | 179,183,000 | 15,482,000 |
| 2024-06-30 | 10-Q | 98,578,000 | -15,479,000 | -0.17 | 179,602,000 | 29,206,000 |
| 2024-03-31 | 10-Q | 94,666,000 | -19,889,000 | -0.22 | 204,532,000 | 41,296,000 |
| 2023-12-31 | 10-K | 324,239,000 | -83,068,000 | -0.92 | 209,240,000 | 57,025,000 |
| 2023-09-30 | 10-Q | 82,035,000 | -17,419,000 | -0.19 | 218,353,000 | 71,849,000 |
| 2023-06-30 | 10-Q | 80,224,000 | -16,897,000 | -0.19 | 229,959,000 | 84,722,000 |
| 2023-03-31 | 10-Q | 76,192,000 | -29,998,000 | -0.33 | 234,633,000 | 98,406,000 |
| 2022-12-31 | 10-K | 252,483,000 | 152,000 | -0.21 | 261,665,000 | 123,175,000 |
| 2022-09-30 | 10-Q | 64,977,000 | -2,674,000 | -0.17 | 283,802,000 | 127,934,000 |
| 2022-06-30 | 10-Q | 60,921,000 | -5,453,000 | -0.06 | 189,740,000 | 123,983,000 |
| 2022-03-31 | 10-Q | 55,161,000 | 19,286,000 | 0.21 | 206,512,000 | 131,998,000 |
| 2021-12-31 | 10-K | 203,003,000 | -10,927,000 | -0.16 | 203,439,000 | 104,159,000 |
| 2021-09-30 | 10-Q | 52,275,000 | -2,980,000 | -0.05 | 230,299,733 | 47,533,000 |
| 2021-06-30 | 10-Q | 49,844,000 | 3,205,000 | 0.05 | 230,754,006 | 50,402,000 |
| 2021-03-31 | 10-Q | 48,580,000 | -996,000 | -0.02 | 231,036,262 | 47,146,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Kaushal Mohit | Director | Open Market Sale | -38,433 | 3.50 | -134,534.72 | -8,8% | |
| 2026-04-14 | Kaushal Mohit | Director | Open Market Sale | -57,286 | 3.50 | -200,598.39 | -13,1% | |
| 2026-04-09 | Chernett Jorey | 10% Owner | Open Market Purchase | 20,000 | 3.10 | 62,000.00 | +4,0% | |
| 2026-03-27 | Chernett Jorey | 10% Owner | Open Market Purchase | 27,429 | 2.96 | 81,189.84 | +5,3% | |
| 2026-03-26 | Chernett Jorey | 10% Owner | Open Market Purchase | 50,000 | 3.15 | 157,500.00 | +10,3% | |
| 2026-03-24 | Chernett Jorey | 10% Owner | Open Market Purchase | 125,000 | 3.11 | 388,750.00 | +25,4% | |
| 2026-03-20 | Chernett Jorey | 10% Owner | Open Market Purchase | 25,000 | 3.35 | 83,750.00 | +5,5% | |
| 2026-03-17 | Chernett Jorey | 10% Owner | Open Market Purchase | 75,000 | 3.42 | 256,500.00 | +16,7% | |
| 2026-03-16 | Chernett Jorey | 10% Owner | Open Market Purchase | 60,985 | 3.29 | 200,640.65 | +13,1% | |
| 2026-03-13 | Chernett Jorey | 10% Owner | Open Market Purchase | 263,000 | 2.92 | 767,960.00 | +50,1% | |
| 2026-01-02 | Carter Robert Ross | Officer, Chief Financial Officer | Open Market Sale | -247 | 3.56 | -879.32 | -0,1% | |
| 2025-12-15 | Hively Brad | Director | Open Market Sale | -13,333 | 3.77 | -50,290.74 | -3,3% | |
| 2025-11-18 | Pacala Mark L | Director | Open Market Sale | -46,630 | 4.00 | -186,520.00 | -12,2% | |
| 2025-11-18 | Pacala Mark L | Director | Open Market Sale | -2,160 | 4.00 | -8,640.00 | -0,6% | |
| 2025-11-18 | Pacala Mark L | Director | Open Market Sale | -1,210 | 4.00 | -4,840.00 | -0,3% | |
| 2025-09-04 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -6,018,168 | 3.09 | -18,596,139.12 | -1214,3% | |
| 2025-09-04 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -681,832 | 3.09 | -2,106,860.88 | -137,6% | |
| 2025-08-19 | Hively Brad | Director | Open Market Sale | -20,221 | 4.06 | -82,097.26 | -5,4% | |
| 2025-06-05 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -673,676 | 3.05 | -2,054,711.80 | -134,2% | |
| 2025-06-05 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -76,324 | 3.05 | -232,788.20 | -15,2% | |
| 2025-06-03 | Hively Brad | Director | Open Market Sale | -1,867,605 | 2.87 | -5,360,586.63 | -350,0% | |
| 2025-06-03 | Hively Brad | Director | Open Market Sale | -108,532 | 2.87 | -311,519.40 | -20,3% | |
| 2025-05-20 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -1,796,468 | 2.71 | -4,873,638.04 | -318,2% | |
| 2025-05-20 | M33 Growth I L.P. | Director, 10% Owner | Open Market Sale | -203,532 | 2.71 | -552,161.96 | -36,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.